Cizzle Bio shared on LinkedIn:
“The American Lung Association is advocating for broader insurance coverage for biomarker testing – a policy shift that could significantly enhance early lung cancer detection.
At Cizzle Bio, we stand behind this initiative. Our CIZ1B biomarker blood test offers a minimally invasive, accurate, and scalable solution to catch lung cancer early – when it’s most treatable.
Read how our work aligns with the ALA’s vision.”
Read article about Lung Cancer on OncoDaily.
